Compare Agora Inc (API) vs 10X Genomics Inc (TXG) Price & Performance

Agora, Inc. (API) trades at $4.46, up 7.47% today, with a bullish technical signal driven by moving averages. The company reported Q1 2026 EPS of $0.01, beating expectations, and shows improving fundamentals with 2025 revenue of $141.06M and net income of $9.53M. Recent news highlights its Q2 2026 earnings report scheduled for August 13, 2026.

Outlook is positive with analyst consensus at 60% buy, supported by a low P/B of 0.68 and strong cash flow growth. Risks include high P/E of 50.68 and competitive pressures in AI technology. The stock offers value potential if earnings growth continues, but volatility may persist near-term.

TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.

The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.